For those… who grew up in the “this is your brain on drugs” era, it’s hard to let go of stigma – and the mental image of an egg sizzling on a hot pan. But as a growing number of states and cities move to decriminalize… Healing the healers is a win-win, and everyone can…
Citing the medical benefits of psilocybin, nine U.S. cities and the State of Oregon have decriminalized or legalized psilocybin… In Oregon, the Research Subcommittee of the Oregon Psilocybin Advisory Board, composed of physicians, biologists and public health officials, analyzed the research and concluded that “high quality phase [I and II] clinical trials suggest that psilocybin is efficacious…
…the authors of the new study claim to have developed an extremely cheap method of producing psilocybin… “In less than [two] days, we successfully produced approximately 300 mg/L of psilocybin under simple conditions with easily sourced equipment and supplies,” write the study authors. “This work demonstrates the biosynthesis of psilocybin at concentrations in the 100s…
Grant Project 5R01MH084894-12: Our published data and the preliminary data presented here support our working hypothesis that inter-family GPCR heteromerization affects structure, sub-cellular localization and function of both 5-HT2AR and mGluR2 in living mammalian cells. Our data are also consonant with the hypothesis that a single dose of hallucinogenic 5-HT2AR agonists induces fast-acting and long-lasting…
Funding from the National Institute of Health [NIH], which tends to award larger grants than philanthropists, allows researchers to delve more into the details, Johnson says. Grant Project Number 1K23MH122777-01A1: We hypothesize that psilocybin will result in increased (i.e. normalized) intra-DMN functional connectivity in OCD, and that this will correlate with any clinical change (Aim 1). Baseline…
“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University. Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators…
“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University. Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators…
The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture… psilocin and psilocybin for clinical trial and research purposes… stated that its objective was to assist in the development of new federally approved therapies. …increased its production goals for psilocin and psilocybin, which are the main psychoactive components of magic mushrooms. Initially, the…
…[is mandated] to develop a long-term strategic plan that ensures safety, accessibility, and affordability on psilocybin services. Measure 109 requires the Board to create a system for psilocybin services that is safe, equitable, and accessible… Original Article (Truffle Report):Oregon psilocybin board partners with harvard’s poplarArtwork Fair Use: Another Believer
“What about under the Right to Try law, though?” asked Judge Ikuta. “Is there a pathway where they could apply under the Right to Try Act?” No, the lawyer for DEA replied. “As the agency indicated in its letter, there’s no procedure available under the Right to Try Act, because the Right to Try Act…
Recent Comments